Early increase of the synaptic blood marker β‐synuclein in asymptomatic autosomal dominant Alzheimer's disease
Authors:
Open Access
- 10 April 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (4) , e70146
Abstract
INTRODUCTION: β‐synuclein is a promising blood marker to track synaptic degeneration in Alzheimer's disease (AD) but changes in preclinical AD are unclear.METHODS: We investigated serum β‐synuclein in 69 cognitively unimpaired mutation non‐carriers, 78 cognitively unimpaired AD mutation carriers (asymptomatic AD), and 31 symptomatic mutation carriers from the Dominantly Inherited Alzheimer Network.RESULTS: β‐synuclein levels were already higher in asymptomatic AD mutation carriers compared to non‐carriers and highest in symptomatic carriers. Longitudinal trajectories and correlation analyses indicated that β‐synuclein levels start to rise after amyloid deposition preceding axonal degeneration, brain atrophy and hypometabolism, and cognitive decline. β‐synuclein levels were associated with cognitive impairment and gradually increased with declining cognition.DISCUSSION: Our study supports the use of blood β‐synuclein to track synaptic changes in preclinical AD and as a surrogate marker for cognitive impairment which might be used in early diagnosis and to support patient selection and monitoring of treatment effects in clinical trials.Highlights: Blood β‐synuclein levels were already higher in asymptomatic Alzheimer's disease (AD) mutation carriers. Blood β‐synuclein levels were highest in symptomatic AD mutation carriers. Blood β‐synuclein levels start to rise 11 years before symptom onset. Rise of β‐synuclein precedes axonal degeneration, brain atrophy, and cognitive decline. β‐synuclein levels gradually increased with declining cognition.Keywords
Funding Information
- National Institute on Aging
- Alzheimer's Association (SG‐20‐690363‐DIAN)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
This publication has 24 references indexed in Scilit:
- Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s diseaseBrain, 2020
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s diseaseNature Medicine, 2020
- Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer’s DiseaseJournal of Proteome Research, 2020
- Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's diseaseAlzheimer's & Dementia, 2019
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s diseaseNature Medicine, 2019
- Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer diseaseNeurology, 2018
- C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's diseaseAlzheimer's & Dementia, 2015
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Alzheimer's Disease Is a Synaptic FailureScience, 2002
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991